AMVUTTRA Gets Priority Nod for Rare Pediatric Conditions via Voucher
Published Date: 4/21/2025
Notice
Summary
The FDA just gave the green light to AMVUTTRA (vutrisiran) for a rare kid’s disease, using a special priority review voucher to speed things up. This means faster access to important medicine for families and shows the FDA’s commitment to helping rare pediatric conditions. The approval happened on March 20, 2025, marking a big win for patients and drug developers alike.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Approves AMVUTTRA for Rare Pediatric Disease
If you are a parent or guardian of a child with a rare pediatric disease, the FDA approved AMVUTTRA (vutrisiran) on March 20, 2025. The approval (Supplement-06) redeemed a Rare Pediatric Disease Priority Review Voucher, which the notice says was used for this product's review.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12167 — Andrew Jonathan Morgan: Final Debarment Order
Andrew Jonathan Morgan is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He didn’t respond to the FDA’s notice, so the ban started on June 17, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping things safe and legal.
2026-12165 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule
The FDA is officially putting the ingestible gastrointestinal blood detection capsule into Class II, meaning it now has special safety rules but fewer hurdles than before. This change helps patients get access to this cool, innovative device faster and keeps it safe and effective. The new classification is effective June 17, 2026, and could save time and money for makers and users alike.
2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
Previous / Next Documents
Previous: 2025-06784 — Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; TREMFYA (guselkumab)
The FDA just gave the green light to TREMFYA (guselkumab) for a rare pediatric disease, using a special priority review voucher. This means faster approval for treatments that kids with rare diseases really need. The approval happened on March 20, 2025, helping patients get access sooner and encouraging companies to develop more rare disease medicines.
Next: 2025-06786 — Action Levels for Lead in Processed Food Intended for Babies and Young Children; Guidance for Industry; Availability; Correction
The FDA fixed a mistake in a January 2025 notice about lead limits in baby and toddler foods. This guidance helps food makers keep lead levels safe for little ones. No new rules or costs—just a clearer message to protect kids.